Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

8
Fortescue puts pressure on Atlas Iron over port development

2018-06-27 australianmining.com.au
Atlas Iron has reinforced its position as a potential developer of facilities at Port Hedland, saying that it has no exclusive rights at the major Western Australian iron ore port in this regard.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

4
Gina Rinehart makes $390m takeover bid Atlas Iron

2018-06-18 theage.com.au
Gina Rinehart has made a takeover bid for 100 per cent of Atlas Iron's shares, as the intriguing battle for control of the junior iron ore miner heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Gina Rinehart makes $390m takeover bid Atlas Iron

2018-06-18 smh.com.au
Gina Rinehart has made a takeover bid for 100 per cent of Atlas Iron's shares, as the intriguing battle for control of the junior iron ore miner heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Atlas Iron in trading halt, pending control proposal announcement

2018-06-18 theage.com.au
Iron ore miner Atlas Iron on Monday sought a trading halt of its shares pending an announcement regarding a "control transaction proposal" as the race for its ownership heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Atlas Iron in trading halt, pending control proposal announcement

2018-06-18 smh.com.au
Iron ore miner Atlas Iron on Monday sought a trading halt of its shares pending an announcement regarding a "control transaction proposal" as the race for its ownership heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

8
Battle over Atlas Iron takes new turn

2018-06-08 theage.com.au
The intriguing corporate battle over the future of junior iron ore miner Atlas Iron has taken a new turn, with Atlas revealing on Friday afternoon that it could "explore discussions with other parties" about its future, after it reached agreement with Mineral Resources to change a recently developed Scheme Implementation Deed between the two companies.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

8
Battle over Atlas Iron takes new turn

2018-06-08 smh.com.au
The intriguing corporate battle over the future of junior iron ore miner Atlas Iron has taken a new turn, with Atlas revealing on Friday afternoon that it could "explore discussions with other parties" about its future, after it reached agreement with Mineral Resources to change a recently developed Scheme Implementation Deed between the two companies.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...